BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
About this episode
Maha Radhakrishnan, M.D. discusses her transition from big pharma and biotech to private equity investing and insights on late-stage asset deals.
We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic in...
More episodes of Business Of Biotech
- Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
- Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
- Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
- Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.